<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Buyse, Gunnar</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Idebenone Delays Respiratory Decline in Duchenne Muscular Dystrophy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-20 11:31:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-7</style></pages><abstract><style  face="normal" font="default" size="100%">The randomized phase 3 DELOS trial was designed to evaluate idebenone, a synthetic quinone compound, in Duchenne muscular dystrophy. The data showed that idebenone was safe and well tolerated, and it significantly reduced loss of respiratory function in patients aged 10 to 18 years.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>